Business Wire

Vista Entertainment Solutions and Movio Go Live with Yorck Kinogruppe, Germany’s Largest Arthouse Cinema Circuit

Del

Vista Group International (NZX & ASX: VGL) companies Vista Entertainment Solutions, the leading provider of cinema management software for global cinema exhibition, and Movio, the worldwide leader in marketing data analytics, are delighted to announce that they are now live with Yorck Kinogruppe, Germany’s premier arthouse cinema group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180515006830/en/

Yorck Kinogruppe is the largest cinema association in Berlin with 14 theatres and an open-air cinema. The theatres show a cross-section of films in some of Berlin’s most revered buildings, many of which have been saved from destruction and restored through the efforts of Yorck Kinos.

Vista Cinema and Movio supported the launch of Yorck Kinogruppe’s seven-screen arthouse, Delphi Lux, in the heart of Berlin, which opened last year. Now Vista is rolling out its VDF certified software to Yorck’s remaining cinemas in Berlin.

The Babylon cinema in the Kreuzberg district moved over to Vista last month and was the first cinema in Europe to adopt the latest in innovation of Vista Cinema Version 5 (V5).

Mischa Kay, Managing Director, Vista EMEA, says: “Working with a German cinema and film institution such as Yorck has been a tremendous privilege for Vista. Yorck’s commitment to cutting edge technology is displayed by their early adoption of Vista Cinema V5.”

Alongside the Vista rollout, Movio has been working with Yorck Kinogruppe to seamlessly integrate the Movio Cinema software into Yorck’s customer database. This integration work has now been completed and Movio is bringing in real-time customer data from the Vista system, along with other data sources, providing Yorck with a comprehensive view of their customers. These customer insights will then be used by the Yorck team to deliver highly targeted and measurable direct marketing campaigns.

“We are thrilled to be working with the Yorck team to improve the understanding of their audiences and giving them the insights to develop more targeted and relevant marketing campaigns. The Yorck Kinogruppe brand has such strong resonance with Berlin movie-goers and Movio’s software will help the Yorck team to strengthen their customer relationships even further,” says Sarah Lewthwaite, Movio’s Managing Director, EMEA.

Christian Brauer, CEO of Yorck Kinogruppe, says: “Thanks to Vista and Movio we now have unbelievable new opportunities to offer our customers the perfect cinematic experience. We have moved the digital future in a new direction.”

About Vista Group International:

Vista Group International (Vista Group) is a public company, listed on both the New Zealand and Australian stock exchanges (NZX & ASX: VGL). The Group provides software and additional technology solutions across the global film industry. Cinema management software is provided by Vista Entertainment Solutions (Vista Entertainment), the core business of the Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based SaaS software for the Independent Cinema Market), movieXchange (connecting the movie industry to simplify the promotion and sale of movie tickets), Maccs (film distribution software), Numero (box office reporting software for film distributors and cinemas), Cinema Intelligence (business intelligence solutions), Powster (creative studio and marketing platform for movie studios) and Flicks (moviegoer ‘go to’ portal for movie information) provide an innovative range of complementary products across additional film industry sectors, from production and distribution, to cinema exhibition through to the moviegoer experience. Vista Group has offices located in New Zealand (Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico City, South Africa, the Netherlands and Romania.

Website: www.vistagroup.co
LinkedIn: www.linkedin.com/company/vista-group-limited

About Vista Entertainment Solutions:

Vista Entertainment Solutions Ltd (‘Vista Cinema’) is the world leader in cinema management software solutions with installations in more than 90 countries around the world and an estimated 38% global market share in the Large Cinema Circuit market. The Vista Cinema software product line comprises multiple modules, integrated and scalable, suited to cinema exhibitors operating 20+ screens and 100s of cinemas. Vista Cinema is headquartered in Auckland, New Zealand, and has subsidiaries incorporated in Los Angeles, London, Shanghai, Beijing, Cape Town and Mexico City.

Website: www.vista.co
Twitter: @VistaCinema
LinkedIn: www.linkedin.com/company/vista-entertainment-solutions

About Movio:

Movio is the global leader in marketing data analytics and campaign management solutions, revolutionizing the way the film industry interacts with moviegoers. With a global database of over 100 million moviegoers, 750 million behavioral and transactional records and more than 5000 movie titles, Movio is the world’s most comprehensive source of moviegoer data. The company’s investment in data science and machine learning has produced market-leading technologies that redefine the possibilities of movie marketing. Movio empowers marketers to connect moviegoers with their ideal movie via online and offline channels, and link campaign data with actual ticket purchases to close the loop and measure campaign effectiveness.

Website: www.movio.co
Twitter: @MovioHQ
LinkedIn: www.linkedin.com/company/movio

About Yorck Kinogruppe:

Originally founded in 1978, Yorck-Kino GmbH is one of Berlin’s biggest cinema operators, with 12 cinemas and an open-air cinema. Yorck Kinogruppe is a proudly independent chain which believes in putting on fantastic films in state-of-the-art cinemas with superb screens, first-class sound and comfortable seating for customers. Many of its cinemas host international premieres and screenings at the prestigious Berlin International Film Festival.

From great theatre palaces to charming small theatres, Yorck Kinogruppe offers the complete art house cinema experience.

Website: www.yorck.de
Twitter: @Yorck Kinos

Contact information

Media Contacts:
For Vista Group International/EMEA
Sharon Heideman, +44 20 8563 4490
sharon.heideman@vista.co
or
For Vista Group International/NZ (HQ)
Christine Fenby, +64 21 727 006
christine.fenby@vista.co
or
For Yorck Kinogruppe
Katja Schubert, +49 30 212 980 78
schubert@yorck.de

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third